Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Rhea-AI Summary

Illumina (NASDAQ: ILMN) announced on Nov 10, 2025 that Illumina Protein Prep, commercially launched in September, is in use by more than 40 customers across 16 sites and has processed over 40,000 samples, offering a discovery panel of > 9,500 proteins at a claimed low cost per protein target.

Customers include Sydney Mass Spectrometry (first Asia Pacific site), Genomics England (reported a 7.5% increase in disease classification when integrating proteomics with genomics), and PRECISE-SG100K (running 10,000 plasma samples). Illumina also noted a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, subject to regulatory clearance.

Positive

• >40 customers across 16 sites
• Processed > 40,000 samples
• Discovery panel of > 9,500 proteins
• Genomics England: 7.5% increase in disease classification
• PRECISE-SG100K running 10,000 plasma samples

Negative

• Acquisition of SomaLogic subject to regulatory clearance
• Scaling and manufacturing reliant on third-party suppliers
• Customer acceptance of new product is uncertain

Insights

Commercial strategy analyst

Rapid commercial uptake and major collaborations suggest meaningful near-term market traction for Illumina Protein Prep.

Illumina Protein Prep shows clear early commercial momentum with "more than 40" customers across 16 sites and over 40,000 samples processed since launch, plus institutional adopters like Sydney Mass Spectrometry and Genomics England. The product's reported panel of "over 9500 proteins" and integration with Illumina's DRAGEN and Connected Multiomics stack create a bundled hardware-software offering that lowers technical barriers for labs transitioning from mass spectrometry.

Key dependencies and risks include sustained customer adoption beyond early access, reproducibility versus existing mass-spectrometry workflows, and the pending regulatory clearance tied to the SomaLogic acquisition. Watch adoption metrics and benchmarking outcomes (for example, Sydney Mass Spectrometry's planned comparisons and Genomics England's expanded validation after the reported 7.5% increase in disease classification) over the next 6–18 months for signs of durable commercial uptake.

Translational proteomics scientist

Early multiomics integrations produced measurable diagnostic gains, supporting scientific utility for large-cohort studies.

Proteomics integration with genomics shows concrete value: Genomics England reported a 7.5% increase in disease classification when proteomics was added to genomics, and PRECISE-SG100K plans to run 10,000 plasma samples, indicating the solution can scale to biobank-sized cohorts. The platform claims broad proteome coverage and identified cohort-level differences in a metabolic-disease dietary trial at Sydney Mass Spectrometry, suggesting usefulness for discovery-stage and translational projects.

Risks and validation needs are straightforward: independent benchmarking versus established mass-spectrometry datasets, replication of candidate proteins at the individual level, and transparent reporting of sensitivity/specificity for clinically relevant markers. Track next-stage publications, the outcome of Sydney Mass Spectrometry's benchmarking, and Genomics England's expanded validation over the coming 12–24 months to confirm reproducibility and clinical-grade performance.

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed

Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale

Recent collaborations and projects including Genomics England and PRECISE-SG100K highlight advancements in proteomic profiling across diverse populations and research areas

SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at the lowest cost per protein target for more than 40 customers across 16 sites globally. Labs of all sizes are creating powerful layers of omic data for a range of diseases that enrich datasets generated by biobank programs around the world.

"We believe in the power of proteomics to give research and clinical labs—big and small—the deepest look into the biology underwriting human health," said Steve Barnard, PhD, chief technology officer of Illumina. "Our customers are harnessing the potential to enrich genomic studies at scale with exceptional specificity, sensitivity, and precision, transforming real-world insights into impactful discoveries."

Illumina Protein Prep empowers researchers to seamlessly integrate comprehensive proteomics into large-scale genomics studies, dramatically accelerating breakthroughs across cancer and cardiometabolic and immunologic diseases. Illumina is providing the AI-driven infrastructure to fully realize this vision with DRAGEN and Illumina Connected Multiomics, delivering both secondary and tertiary analysis in one workflow.

Depending on the use case, the Illumina Protein Prep solution offers an accessible alternative or complement to mass spectrometry, allowing researchers to derive transformative insights, increasing their discovery power.

Sydney Mass Spectrometry adopts Illumina Protein Prep to expand proteomic offerings

As the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, Sydney Mass Spectrometry recently completed their first real-world experiment using blood plasma samples from a clinical trial to study dietary interventions in subjects with metabolic disease. Illumina Protein Prep identified significant differences between cohorts on a grouped basis, leading researchers on a path to further validate several novel candidates.

"We believe Illumina Protein Prep is a powerful proteomics solution to fuel large-scale strategies for various proteome- and genome-matched projects for translational research," said Professor Stuart Cordwell, PhD, academic director of Sydney Mass Spectrometry, The University of Sydney. "As a lab that has historically focused on mass spectrometry, we see a robust opportunity for these technologies to serve as alternatives or complements due to Illumina Protein Prep's broad, dynamic range and large discovery panel of over 9500 proteins."

The proteomic insights were all generated using Illumina platforms and software. Next, the facility intends to benchmark existing large clinical mass spectrometry studies with Illumina Protein Prep.

Genomics England expanded study advances rare disease research

As an early-access customer, Genomics England used Illumina Protein Prep as part of a larger multiomics initiative for its 100,000 Genomes Project. Initial data revealed last month at the annual ASHG conference in Boston demonstrated a 7.5% increase in disease classification when genomics and proteomics were integrated in previously undiagnosed patients. The expanded study aims to validate the initial findings and discoveries of abundant differential proteins in specific disease categories.

"Our experience with Illumina Protein Prep continues to validate my confidence in the potential of proteomics to revolutionize our understanding of both rare and common disease," said Professor Matthew Brown, chief scientific officer of Genomics England. "Data from this study and others like it will create a ripple effect for large-scale studies around the world—every new layer of omic insights increases the quality and depth of the pathways we can uncover, from genetic variants to protein expression to drug discovery." 

Proteomics is key to decoding disease across diverse datasets

Biobanks are increasingly focused on understanding molecular mechanisms of disease in historically underrepresented populations. Now, proteomics is creating the vital bridge between population-specific genetic variants and their affected proteins.

Singapore's PRECISE-SG100K study is using Illumina Protein Prep to run 10,000 plasma samples to expand upon its previous proteomic profiling project, with a goal to develop a standardized dataset that can be used to interrogate potential therapeutic targets.

"We established this program with the intent to reach a deeper understanding of how diseases develop and discover better treatments in Asian populations," said Professor John Chambers, PhD, chief scientific officer of PRECISE and lead PI of SG100K. "Building on our collaboration with Illumina, we are looking forward to making our dataset even more impactful for researchers seeking representative multiomic markers for precision medicine."

Additional proteomics news from Illumina

Illumina showcased Illumina Protein Prep and Illumina Connected Multiomics this week at the Human Proteome Organization World Congress. Presentations will be available to view on demand here after the conference. For more on Illumina's multiomics solutions, follow this link.

In June, Illumina announced a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic. Until the transaction closes, which is subject to customary closing conditions, including the receipt of required regulatory clearance, Illumina and SomaLogic will continue to operate as separate and independent entities.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations; and (iv) our ability to obtain any required regulatory clearances to close our acquisition of SomaLogic, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
 Illumina Investor Relations
 858-291-6421
 IR@illumina.com

Media:
 Christine Douglass
 PR@illumina.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-protein-prep-delivers-groundbreaking-precision-in-ngs-proteomics-for-more-than-40-customers-ranging-from-academic-institutions-to-large-national-biobanks-302610407.html

SOURCE Illumina, Inc.

FAQ

What did Illumina (ILMN) announce about Illumina Protein Prep on Nov 10, 2025?

Illumina said Illumina Protein Prep is used by > 40 customers, processed > 40,000 samples, and offers a discovery panel of > 9,500 proteins.

How many samples has Illumina Protein Prep processed as of Nov 10, 2025?

Illumina reports the solution has processed over 40,000 samples.

What improvement did Genomics England report using Illumina Protein Prep with genomics data?

Genomics England reported a 7.5% increase in disease classification when integrating proteomics with genomics.

What is the size of the Illumina Protein Prep protein panel announced Nov 10, 2025?

Illumina Protein Prep provides a discovery panel of more than 9,500 proteins.

What does the June definitive agreement with Standard BioTools (LAB) mean for the SomaLogic deal?

Illumina announced a definitive agreement to acquire SomaLogic from Standard BioTools, but closing is subject to required regulatory clearance and customary conditions.

Which Asia Pacific facility first adopted Illumina Protein Prep and what did it show?

Sydney Mass Spectrometry (University of Sydney) is the first wider Asia Pacific facility and reported identification of significant cohort differences in a metabolic disease trial.